-transparent.png){kind=logo}
5-aminosalicylates (5-ASA) remain an important strategy in the induction and maintenance of remission of inflammatory bowel diseases especially in ulcerative colitis. The prototypical drug of this class, sulfasalazine is generally well tolerated with severe hypersensitivity reactions and hepatotoxicity also described within the literature. When approaching a patient with an adverse reaction to 5-ASA, it can be difficult to differentiate clinically between a sulfa allergy versus a 5-ASA allergy versus a malignancy. We report on a case with initial signs and symptoms suggestive of a sulfa/5-ASA allergy that was subsequently found to be malignant in nature.
Related Publications
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
November 2003,
Gastrointestinal endoscopy,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
May 2017,
Pediatrics international : official journal of the Japan Pediatric Society,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
August 1985,
The American journal of gastroenterology,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
June 2013,
The American journal of gastroenterology,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
March 2019,
ACG case reports journal,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
August 2019,
The Malaysian journal of pathology,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
September 1996,
Der Internist,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
December 2017,
International journal of rheumatic diseases,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
April 2002,
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
L M Kong, and
K C Fok, and
A Tsui, and
C Qian, and
L Fisher
January 2011,
Drug and therapeutics bulletin,
